GILD vs. RPRX: Gilead Sciences vs. Royalty Pharma Stock Comparison

Company Profile

Gilead Sciences (GILD) and Royalty Pharma (RPRX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GILD is classified in Biotechnology while RPRX is classified in Pharmaceuticals.

Gilead Sciences (GILD) has more than two decades of public-market history since January 22, 1992, whereas Royalty Pharma (RPRX) listed on June 16, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Gilead Sciences (GILD) reports a negative ROE of -22.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Royalty Pharma (RPRX) reports 12.09%, ranking against industry peers normally.

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile Royalty Pharma (RPRX) reports 25.70%, ranking against industry peers normally.

Both Gilead Sciences (GILD) at 42.43% and Royalty Pharma (RPRX) at 81.32% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Gilead Sciences (GILD) at 2.39% and Royalty Pharma (RPRX) at 5.06% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than Royalty Pharma (RPRX) at 23.09%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Both Gilead Sciences (GILD) at 1.38 and Royalty Pharma (RPRX) at 1.29 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both balance sheets lean debt-heavy versus peers, but GILD is more stretched: Royalty Pharma (RPRX) at 0.88 sits in the higher-leverage quartile and Gilead Sciences (GILD) at 2.02 is above its industry benchmark range.

Financial Strength Metrics

Dividends

Both Gilead Sciences (GILD) at 1.94% and Royalty Pharma (RPRX) at 1.37% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both Gilead Sciences (GILD) at 43.46% and Royalty Pharma (RPRX) at 60.46% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Royalty Pharma (RPRX) trades at 43.99 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

On P/S ratio, both Gilead Sciences (GILD) at 6.68 and Royalty Pharma (RPRX) at 14.79 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Royalty Pharma (RPRX) at 4.39 sits near its industry’s typical P/B ratio, while Gilead Sciences (GILD) at 15.88 prices above its benchmark range — GILD looks rich relative to book.

Valuation Metrics